Skip to content
Psychedelic Alpha· Evander·· 18 days agoAI score72

Usona completes FDA submission of psilocybin NDA for major depressive disorder

Usona Files Psilocybin for Depression NDA as Race With Compass Tightens

AI summary

Usona Institute has completed its submission of a NDAA new drug application, the formal request asking the FDA to approve a new medicine for sale in the United States.Open the glossary to the US FDAThe Food and Drug Administration, the United States regulator of medicines, medical devices and food.Open the glossary for its psilocybin candidate for major depressive disorder.

Key facts

Compound
Psilocybin
Condition
Depression
Organisation
Usona Institute
Jurisdiction
United States
Source
Psychedelic Alpha (psychedelicalpha.com)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: Psychedelic Alpha · psychedelicalpha.com

Connected to

Compound
Psilocybin
Condition
Depression
Organisation
Usona Institute
Jurisdiction
United States

Other recent items on these topics